BrainLife | Library
CNS Tumors | Diffuse astrocytic and oligodendroglial tumors
Oligodendrogliomas
Oligodendroglioma


Home > Library > CNS Tumors > Diffuse astrocytic and oligodendroglial tumors > Oligodendroglioma



Contents



CASE REPORTS


CLASSIFICATION


DIAGNOSIS


EPIDEMIOLOGY, RISK FACTORS


ETIOLOGY, PATHOGENESIS, PATHOLOGY


FOLLOW-UP, QUALITY OF LIFE


INTEGRATIVE MEDICINE


OVERALL MANAGEMENT


PROGNOSIS


TREATMENT



Case reports




MULTICENTRIC



Vats A, Amit A, Doshi P.
Multicentric high grade oligodendroglioma: a rare entity.
Br J Neurosurg. 2017 Oct 27:1-3. doi: 10.1080/02688697.2017.1396582. Online first. _



SARCOMA-LIKE TUMOR



Shoji T, Saito R, Kanamori M, Sonoda Y, Watanabe M, Tominaga T.
Sarcoma-like tumor originating from oligodendroglioma.
Brain Tumor Pathol. 2016 Jun 22. doi: 10.1007/s10014-016-0268-2. Online first. _



Etiology, Pathogenesis, Pathology



Geevar T, Pai R, Chacko G, Malepathi K, Patel B, John J, Chacko AG, Balakrishnan R, John S.
Molecular profile of tumors with oligodendroglial morphology: Clinical relevance.
Neurol India. 2018 Nov-Dec;66(6):1726-1731. doi: 10.4103/0028-3886.246275. Online 2018 Nov 18. _



Prognosis



Achey RL, Khanna V, Ostrom QT, Kruchko C, Barnholtz-Sloan JS.
Incidence and survival trends in oligodendrogliomas and anaplastic oligodendrogliomas in the United States from 2000 to 2013: a CBTRUS Report.
J Neurooncol. 2017 Apr 10. doi: 10.1007/s11060-017-2414-z. Online first. _




Goel NJ, Abdullah KG, Lang SS.
Outcomes and Prognostic Factors in Pediatric Oligodendroglioma: A Population-Based Study.
Pediatr Neurosurg. 2017 Nov 2. doi: 10.1159/000481458. Online first. _




Laghari AA, Khalid MU, Qadeer N, Shamim MS.
Prognostic value of 1p/19q chromosomal codeletion in patients with oligodendroglioma. [With a review of the literature].
J Pak Med Assoc. 2019 Jan;69(1):132-134. _




Zetterling M, Berhane L, Alafuzoff I, Jakola AS, Smits A.
Prognostic markers for survival in patients with oligodendroglial tumors; a single-institution review of 214 cases.
PLoS One. 2017 Nov 29;12(11):e0188419. doi: 10.1371/journal.pone.0188419. _



Treatment




CHEMOTHERAPY



Iwadate Y, Matsutani T, Hara A, Hirono S, Ikegami S, Kobayashi M, Ito D, Kawauchi D, Horiguchi K, Tamiya A, Higuchi Y.
Eighty percent survival rate at 15 years for 1p/19q co-deleted oligodendroglioma treated with upfront chemotherapy irrespective of tumor grade.
J Neurooncol. 2019 Jan;141(1):205-211. doi: 10.1007/s11060-018-03027-5. Online 2018 Dec 18. _



SURGERY



Alattar AA, Brandel MG, Hirshman BR, Dong X, Carroll KT, Ali MA, Carter BS, Chen CC.
Oligodendroglioma resection: a Surveillance, Epidemiology, and End Results (SEER) analysis.
J Neurosurg. 2017 May 12:1-8. doi: 10.3171/2016.11.JNS161974. Online first. _



SALVAGE TREATMENTS



Kuga D, Hata N, Akagi Y, Amemiya T, Sangatsuda Y, Hatae R, Yoshimoto K, Mizoguchi M, Iihara K.
The Effectiveness of Salvage Treatments for Recurrent Lesions of Oligodendrogliomas Previously Treated with Upfront Chemotherapy.
World Neurosurg. 2018 Mar 16. doi: 10.1016/j.wneu.2018.03.069. Online first. _